4
Changes in Ownership
Kalaris Therapeutics, Inc. Filed Acc 0000899243-21-007332
Chief Commercial Officer sold 2,085 shares at an average $40.67 ($84,787)
From the SEC's structured data for this filing
Trades in this filing
VAN BEEK JEROEN B · Chief Commercial Officer
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2021-02-18 | Sale : show line 1 in the form | −535 | $39.83 | $21,312 | 504,795 | D |
| 2021-02-18 | Sale : show line 2 in the form | −800 | $40.44 | $32,349 | 503,995 | D |
| 2021-02-18 | Sale : show line 3 in the form | −750 | $41.50 | $31,126 | 503,245 | D |
| Open-market sales · 2,085 sh · avg $40.67 · $84,787 | ||||||
Loading xslF345X03/doc4.xml…